Pharmacogenomics - Related Products

Pharmacogenomics -
Related Products

Proteomics: A Key Enabling Tool for Genomics
Authored by Lucy Sannes, Ph.D.,
Published by Cambridge HealthTech Institute in June, 1999
AC906 - 66 pages, Price - $850, ORDER NOW

Single Nucleotide Polymorphisms (SNPs): Commercial and Scientific Prospects
Authored by Ken Rubenstein, Ph.D.,
Published by Cambridge HealthTech Institute in September, 1999
AC909 - Approx. 50 pages, Price - $850, ORDER NOW

Maximizing Productivity in Genomics - Report Article
Goeffrey Ginsburg, M.D., Ph.D., Senior Program Director, Millennium Pharmaceuticals
Published By AdvanceTech Monitor in September, 1999
AM908A - Approx. 20 pages, Price - $295, ORDER NOW

Pharmacogenomics Impact on Early Lead Selection - Report Article
Mark Egerton, Ph.D., Director, Pharmacogenomics, Incyte Pharmacuticals
Published By AdvanceTech Monitor in November, 1999
AM911A - Approx. 20 pages, Price - $295, ORDER NOW

------------------------------------------------------------------------

Proteomics: A Key Enabling Tool for Genomics?
Authored by Lucy Sannes and published by The Cambridge Healthtech Institute (CHI), as part of CHI’s Genomic Pathways Report Series. Published in June, 1999.
AC906 - 66 pages, Price - $850 , ORDER NOW

More than a dozen companies, including Amgen, Biosource Proteomics Inc., Glaxo Wellcome, Hoffmann-La Roche, Incyte Pharmaceuticals, Millennium Pharmaceuticals, and Oxford GlycoSciences, are using proteomics to advance drug or diagnostic discovery and development. Preliminary results suggest that this new field will quickly lead to better pharmaceuticals in certain therapeutic areas, but with hundreds of tools to choose from and dozens of emerging applications, picking the right approach is critical. This new report facilitates such decision making. It forecasts how proteomics will most successfully be used, in which therapeutic areas it will have its first impact, and how its various tools and approaches will evolve.

Proteomic technologies and applications of more than 50 companies are discussed, and detailed profiles, with contact information, are provided for 23 companies.

Written in language targeting business professionals, this report:
Describes proteomics and how it is being used
Evaluates current and emerging tools and approaches
Assesses industry leaders and their strategies
Examines prospects for various therapeutic and other applications

Table of Contents:

I) INTRODUCTION: Why Proteomics?

II) SCIENTIFIC BACKGROUND: The Challenge of Greater Complexity

A. Comparing Proteomics with Genomics

i) Similarities
ii) Differences

B. Using Proteomics and Genomics in a Complementary Fashion

III) THE CURRENT AND EMERGING TECHNOLOGIES: The Search for High Throughput

A. The First Level of Analysis: Protein Separation, Identification, and Characterization

i) Sample Preparation
ii) 2-D Gel Electrophoresis

a. Standard Approaches
b. New Developments
c. Overview

iii) Staining
iv) Image Analysis
v) Mass Spectrometry

a. The Main Technologies
b. Chromatography and Capillary Electrophoresis
c. Protein Identification Software
d. Overview

vi) Protein Chips
vii) Databases
viii) Bioinformatics

B. The Next Level of Analysis: Tools and Approaches for Protein Function Studies

i) Quantification
ii) High-Throughput Expression
iii) Protein-Protein Interactions
iv) Protein Function
v) What's Next?

a. Holistic Approaches
b. Advanced Molecular Modeling (In Silico Biology)

IV) BUSINESS AND STRATEGIC CONSIDERATIONS: The Leaders Are Far Ahead

A. Industry Leaders
B. Selected Tool and Service Providers
C. Bench-Top Platform Technology Providers

V) APPLICATIONS: Early Signs of Valuable Potential

A. Basic Research
B. Diagnostics and Prognostic Indicators
C. Drug Discovery and Development

i) Target Identification and Validation
ii) Pathway Elucidation
iii) Mode of Action
iv) Toxicology
v) Surrogate Markers of Drug Response
vi) Drug Resistance

D. Pathogens
E. Agriculture and Other Areas

VI) OUTLOOK: New Tools and a Context for Managing Data

A. Key Remaining Issues

i) Is 2-D Gel Electrophoresis Replaceable?
ii) Access to Genetic Sequence Information
iii) Plain Skepticism

B. The Future of Proteomics
C. Commentaries from Editorial Board Members

Appendix A: Table of over 50 Companies Involved in Proteomics
Appendix B: Profiles of 23 Key Companies

The Editorial Advisory Board for this report includes:
Claire J. Allan, Glaxo Wellcome; Leigh Anderson, Biosource Proteomics Inc.; Chris Ashton, Oxford GlycoSciences; Walter Blackstock, Glaxo Wellcome; Roger Brent, Molecular Sciences Institute; Carol Giometti, Argonne National Laboratory; Paul J. Godowski, Genentech; Sharan A. Pagano, Genetics Institute; Chris Pearce, Proteome Sciences; Chris Sander, Millennium Predictive Medicine; Jeff J. Seilhamer, Incyte Pharmaceuticals; Jay Snable, Incyte Pharmaceuticals; Alan R. Williamson, Consultant; John R. Yates, University of Washington.

------------------------------------------------------------------------

Single Nucleotide Polymorphisms (SNPs): Commercial and Scientific Prospects - AC909 - Approx. 50 pages, Price - $850,
ORDER NOW

Researchers are racing to identify the estimated 6 to 30 million human SNPs and thereby generate optimal drug targets. These markers of human variation have already provided key information about diseases such as sickle-cell anemia, cystic fibrosis, Down syndrome, Tay-Sachs disease, Alzheimer's disease, and colon cancer. At stake are significant markets for SNP-related technologies, as well as the multibillion-dollar potential of smarter drug discovery approaches, including pharmacogenomics.

This concise, comprehensive, report focuses on the most relevant information. It features a unique combination of technology updates and forecasts, as well as insight, analysis, and commentaries from leading experts in the field.

The report covers:

Current and emerging technologies
Company positions and strategies
Prospects for specific applications
Market potential and dynamics

Editorial Advisory Board Members on this report include: Claire Allan, Glaxo Wellcome; Andy Clark , University of Pennsylvania; Ken Conway, Millennium Predictive Medicine; Colin Dykes, Variagenics; Jeanette Just, Millennium Predictive Medicine; Stephen Kingsmore, Molecular Staging; Eden Martin, Duke Center for Human Genetics; Jan Mous, F. Hoffman-La Roche; Nicholas Schork, Genset; Alan R. Williamson, Consultant; David Wang, Bristol-Myers Squibb.

-----------------------------------------------------------------------

Pharmacogenomics Impact on Early Lead Selection - Report Article
Goeffrey Ginsburg, M.D., Ph.D., Senior Program Director, Millennium Pharmaceuticals
Published By AdvanceTech Monitor in September, 1999
AM908A - Approx. 20 pages, Price - $295, ORDER NOW

Creating a culture aligned to speed
Evaluating existing processes and setting best practice standards and benchmarks
Realigning teams, work processes and automation to increase efficiency
Operations management for genomics
TQM/QC in gene target discovery

------------------------------------------------------------------------

Pharmacogenomics is the elucidation of drug action based on genotyper (DNA) and/or genetic expression (RNA/protein). Through genetic profiling, one can obtain information on likely toxicological effects of compounds in development.
- Identify molecular efficacy and toxicity markers
- Gene Expression and proteomic profiling to predict toxicological outcomes and drug-drug interactions

Top of Page

[Home] [Products] [KnowledgeBase] [Partners] [About Us]